Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965677 | 0.88 | ALOX15 (0.56) | MTNR1AMTNR1BRAB9AL3MBTL1ALOX15 | |
| SCHEMBL10075120 | 0.84 | MAPT (0.50) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL10075116 | 0.83 | TDP1 (0.53) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL14370917 | 0.82 | ALOX15 (0.50) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL4570321 | 0.82 | ALOX15 (0.54) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL9673890 | 0.81 | MAPT (0.37) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL5486063 | 0.81 | LMNA (0.50) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL10075121 | 0.80 | ALOX15 (0.44) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL10075117 | 0.80 | LMNA (0.51) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT | |
| SCHEMBL896992 | 0.80 | ALDH1A1 (0.53) | MTNR1AMTNR1BRAB9AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150111-B1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-20120252836-A1 | 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120252836-A1 | 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | P2RY12, P2RY13, P2RY6 | MTNR1A 83/4885MTNR1B 72/4885RAB9A 2600/4885 |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | MTNR1A 215/4885MTNR1B 321/4885RAB9A 4088/4885 |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | MTNR1A 113/4885MTNR1B 165/4885RAB9A 3893/4885 |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | MTNR1A 113/4885MTNR1B 165/4885RAB9A 3893/4885 |
| US-20120252836-A1 | 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | MTNR1A 110/4885MTNR1B 163/4885RAB9A 4036/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | MTNR1A 90/4885MTNR1B 180/4885RAB9A 2775/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | MTNR1A 215/4885MTNR1B 321/4885RAB9A 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.